As ARID1A is mutated in about one-half of clear cell ovarian carcinomas, the above observations suggest that such patients could be further stratified on the basis of various components of EZH2 pathways to maximize the therapeutic effects of EZH2 inhibitors. The gene discussed is EZH2; the disease is ovarian clear cell cancer.